IRIS

2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)

CASRN 68631-49-2 | DTXSID4030047

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (15 pp, 166 K) Last Updated: 06/30/2008

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 2 x 10 -4 Neurobehavioral effects NOAEL : 0.45
mg/kg
3000 Low

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (15 pp, 166 K) Last Updated: 06/30/2008
Information reviewed but value not estimated.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (15 pp, 166 K) Last Updated: 06/30/2008

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5,5'-hexabromodiphenyl ether.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (15 pp, 166 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (15 pp, 166 K)

Not assessed under the IRIS Program.


Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.